Efficacy and Safety of Tabalumab, an Anti–B-Cell–Activating Factor Monoclonal Antibody, in a Heterogeneous Rheumatoid Arthritis Population

doi:https://doi.org/10.1097/rhu.0000000000000276

Efficacy and Safety of Tabalumab, an Anti–B-Cell–Activating Factor Monoclonal Antibody, in a Heterogeneous Rheumatoid Arthritis Population

Mark C. Genovese,Gregg J. Silverman,Paul Emery,Ramesh C. Gupta,Anne Gill,Melissa Veenhuizen+4 more-2015-07-23-JCR Journal of Clinical Rheumatology

9

TL;DRAbstract

Although tabalumab administration resulted in biologic activity, as demonstrated by changes in B cells and immunoglobulins, targeting BAFF-dependent pathways alone is not sufficient to significantly reduce rheumatoid arthritis disease activity.

Chat with Paper

AI Agents for this Paper

Although tabalumab administration resulted in biologic activity, as demonstrated by changes in B cells and immunoglobulins, targeting BAFF-dependent pathways alone is not sufficient to significantly reduce rheumatoid arthritis disease activity.

Keywords

MedicineRheumatoid arthritisPlaceboInternal medicinePopulationAdverse effectIncidence (geometry)Clinical endpoint

Chat

Click to start Chat